BERKELEY HEIGHTS, NJ, USA and SHANGHAI, China I June 23, 2025 I Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage ...

TOKYO, Japan & BASKING RIDGE, NJ, USA I June 23, 2025 I DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and ...

OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...

MUNICH, Germany I June 24, 2025 I Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, ...

Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo End of Phase 2 meeting request has ...

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression ...

NEW YORK, NY, USA I June 23, 2025 I Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary ...

ALTB-268 demonstrated therapeutic potential in murine models of colitis and GvHD, supporting its role as an immune checkpoint enhancer in T cell-mediated ...

The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge.

BEIJING, China and BRIDGEWATER, NJ, USA I June 21, 2025 I Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced that the ...

PLAINSBORO, NJ, USA I June 22, 2025 I Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial ...